Certara Enhances Pharmaceutical Innovation with Launch of CoAuthor Generative AI for Regulatory Writing

In a significant advancement for pharmaceutical and biotech industries, Certara, a prominent player in the domain of model-informed drug development, has introduced their novel CoAuthor regulatory writing software. This groundbreaking technology is poised to transform the way medical documents are composed, harnessing the power of generative AI to streamline the intricate process of regulatory submission.

The Next Frontier in Regulatory Documentation

The newest release of Certara's CoAuthor marks a pivotal step in the evolution of regulatory writing software. CoAuthor is engineered to assist medical writers by providing an intuitive system which significantly expedites the creation of regulatory documents, an integral component in the drug approval process. Its advanced features are designed to meet the increasingly complex requirements of global regulatory agencies.

CERT's Commitment to Advancement

CERT, headquartered in Princeton, New Jersey, is renowned for its suite of software products and services that facilitate biosimulation in drug development. The unveiling of CoAuthor reflects the company's incesssent dedication to innovation and its commitment to aiding clients in navigating the challenges of regulatory filings and market access efficiently.

MSFT, An Industry Titan's Continual Growth

Not to be outdone, MSFT, a titan of the tech world, continues to assert its dominance across various sectors, including the development of high-demand software and hardware products. From the universally familiar Microsoft Office suite to its cutting-edge Surface devices, MSFT exemplifies sustained expansion and leadership in the sprawling sphere of technology.

Certara, CoAuthor, Software